What is Accendra Health, Inc.'s earnings per share (EPS)?

Accendra Health, Inc. (ACH) reported diluted earnings per share of -$14.31 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Accendra Health (ACH) Financials

ACH NYSE

Trailing 12 months to June 30, 2026

Revenue $2.6B YoY not available

Net Income -$302.1M YoY not available

EPS (Diluted) -$3.94 n/m YoY

Free Cash Flow -$357.2M n/m YoY

Market Cap $19.5M as of Oct 30, 2026

Price / Sales 0.0x on $2.6B revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACH SEC filings page.

Accendra Health, Inc. (ACH) reported $2.6B in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACH FY2025 2026-10-26

Revenue is still growing, but FY2025 cost pressure and balance-sheet strain turned a formerly cash-generative model into one consuming cash.

FY2025 operating income was positive at $27M, yet operating cash flow was -$102M, so the accounting recovery did not arrive as cash. Free cash flow was -$293M because capital spending of $191M added a second cash use, making reinvestment larger than cash generated by operations.

Revenue rose 3.1% while cost of revenue rose 5.2%, so sales growth did not translate into proportional gross profit. Gross margin fell by 36.1 percentage points to 46.7%, indicating that a major cost or mix change drove the economics rather than volume alone.

Liabilities of $2.9B exceeded assets of $2.5B, leaving the company with negative equity; this is a balance-sheet solvency condition, not merely a weak quarter. The 0.6x current ratio shows current assets did not cover current liabilities, while the reported liquidity comparison equaled 33.2 months of annual operating outflow.

Financial Health Signals

Financial Health Score 22/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Accendra Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Accendra Health, Inc. has an operating margin of 1.0%, meaning the company retains $1 of operating profit per $100 of revenue. Among its peers this margin ranks in the lower range, for a profitability score of 20/100. This is up from -8.1% the prior year.

Growth

Accendra Health, Inc.'s revenue grew a modest 3.1% year-over-year to $2.8B. This slow but positive growth earns a score of 45/100.

Leverage

Liquidity

Accendra Health, Inc.'s current ratio of 0.58 is below the typical benchmark, resulting in a score of 6/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Accendra Health, Inc.'s operations used $101.8M of cash, and capex of $191.0M added to the outflow, for a free cash flow shortfall of $292.7M. This results in a cash flow score of 25/100.

Returns

Altman Z-Score Distress

0.36

Accendra Health, Inc. scores 0.36, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.1B against total assets of $2.5B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

Accendra Health, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing

N/A

Accendra Health, Inc. reported a net loss of $1.1B while operations used $101.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.26x

Accendra Health, Inc. earns $0.26 in operating income for every $1 of interest expense ($27.5M vs $107.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$613.2M

YoY-10.1%

QoQ-2.3%

Accendra Health, Inc. generated $613.2M in revenue in Q2 2026. This represents a decrease of 10.1% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.

EBITDA

$30.6M

YoY+832.5%

QoQ-61.3%

Accendra Health, Inc.'s EBITDA was $30.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 832.5% from the same quarter a year earlier. Against the prior quarter it is down 61.3%.

Net Income

-$89.1M

YoYn/m

QoQn/m

Accendra Health, Inc. reported a net loss of $89.1M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$1.16

YoYn/m

QoQn/m

Accendra Health, Inc. earned -$1.16 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow

-$73.6M

YoYn/m

QoQn/m

5Y CAGRn/m

10Y CAGRn/m

Accendra Health, Inc. recorded an outflow of $73.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$7.7M

YoY-80.0%

QoQ-97.7%

5Y CAGR-30.0%

10Y CAGR-25.2%

Accendra Health, Inc. held $7.7M in cash against $1.7B in long-term debt as of Q2 2026.

Shares Outstanding

77M

YoY-0.4%

QoQ+0.4%

5Y CAGR+0.4%

10Y CAGR+2.1%

Accendra Health, Inc. had 77M shares outstanding in Q2 2026. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

43.0%

YoY-4.6pp

QoQ-1.3pp

Accendra Health, Inc.'s gross margin was 43.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 4.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.

Operating Margin

-5.7%

YoY+0.1pp

QoQ-8.5pp

Accendra Health, Inc.'s operating margin was -5.7% in Q2 2026, reflecting core business profitability. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.5 percentage points.

Net Margin

-14.5%

QoQ-13.5pp

Accendra Health, Inc.'s net profit margin was -14.5% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is down 13.5 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

$47.6M

YoY-17.4%

QoQ+14.3%

5Y CAGR+37.8%

10Y CAGR+29.5%

Accendra Health, Inc. invested $47.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 17.4% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

ACH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACH quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.6B	$2.8B+3.1%	$2.7B+5.0%	$2.6B-74.4%	$10.0B+1.7%	$9.8B+15.4%	$8.5B-7.9%	$9.2B-2.2%	$9.4B+1.1%	$9.3B-4.2%	$9.7B-0.5%	$9.8B+3.5%	$9.4B+4.1%	$9.1B+2.3%	$8.9B+2.8%	$8.6B
Cost of Revenue	$1.5B	$1.5B+5.2%	$1.4B+4.8%	$1.3B-83.6%	$8.1B-1.7%	$8.3B+14.9%	$7.2B-10.9%	$8.1B-3.2%	$8.3B+2.5%	$8.1B-4.6%	$8.5B-0.3%	$8.6B+3.5%	$8.3B+4.0%	$8.0B+0.1%	$7.9B+2.2%	$7.8B
Gross Profit	$980.1M	$1.3B-41.9%	$2.2B+4.4%	$2.1B+16.4%	$1.8B+20.7%	$1.5B+18.1%	$1.3B+13.5%	$1.1B+5.4%	$1.1B-8.6%	$1.2B-1.3%	$1.2B-2.2%	$1.2B+3.8%	$1.2B+4.7%	$1.1B+20.8%	$924.7M+7.8%	$857.5M
R&D Expenses	N/A	N/A	$13.0M0.0%	$13.0M+8.3%	$12.0M-0.8%	$12.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.0B	$1.1B-1.4%	$1.1B+8.1%	$1.0B-35.6%	$1.6B+44.4%	$1.1B+3.4%	$1.0B+1.8%	$1.0B+7.4%	$952.9M-6.3%	$1.0B+4.8%	$970.4M-2.4%	$993.8M+1.0%	$984.1M+13.9%	$863.7M+26.5%	$682.6M+11.8%	$610.7M
Operating Income	$29.4M	$27.5Mn/m	-$217.7M-263.4%	$133.2M-6.8%	$142.9M-61.2%	$368.5M+80.5%	$204.1M+179.0%	$73.2Mn/m	-$352.3M-494.8%	$89.3M-55.3%	$199.6M-0.4%	$200.4M+25.6%	$159.5M-19.5%	$198.1M+0.7%	$196.8M-3.3%	$203.5M
EBITDA	N/A	$242.0Mn/m	-$36.4M-110.6%	$343.6M-7.5%	$371.6M-19.1%	$459.1M+54.3%	$297.5M+56.7%	$189.8Mn/m	-$250.4M-268.4%	$148.7M-41.7%	$255.0M-4.3%	$266.3M+19.5%	$222.9M-10.3%	$248.7M+5.2%	$236.4M-0.5%	$237.7M
Interest Expense	$114.1M	$107.2M-0.4%	$107.6M-7.9%	$116.8M-9.4%	$128.9M+168.0%	$48.1M-42.3%	$83.4M-15.0%	$98.1M+38.2%	$71.0M+123.4%	$31.8M+17.4%	$27.1M-0.3%	$27.1M+49.5%	$18.2M+38.7%	$13.1M-2.2%	$13.4M-2.1%	$13.7M
Income Tax	-$4.9M	$729K-96.5%	$20.9M+227.8%	$6.4Mn/m	-$11.5M-120.8%	$55.2M+152.7%	$21.8Mn/m	-$6.1Mn/m	-$32.4Mn/m	-$15.3M-124.0%	$63.8M-8.7%	$69.8M+16.4%	$60.0M-19.1%	$74.1M-0.3%	$74.4M-0.4%	$74.6M
Net Income	-$302.1M	-$1.1Bn/m	-$362.7Mn/m	-$41.3M-284.5%	$22.4M-89.9%	$221.6M+641.8%	$29.9Mn/m	-$62.4Mn/m	-$437.0M-700.3%	$72.8M-33.1%	$108.8M+5.2%	$103.4M+55.5%	$66.5M-40.0%	$110.9M+1.7%	$109.0M-5.4%	$115.2M
EPS (Basic)	N/A	-$14.31n/m	-$4.73n/m	-$0.54-280.0%	$0.30-90.2%	$3.05+548.9%	$0.47n/m	-$1.03n/m	-$7.28-706.7%	$1.20-31.8%	$1.76+6.7%	$1.65+55.7%	$1.06-39.8%	$1.76+2.3%	$1.72-5.5%	$1.82
EPS (Diluted)	-$3.94	-$14.31n/m	-$4.73n/m	-$0.53-282.8%	$0.29-90.1%	$2.94+525.5%	$0.47n/m	-$1.03n/m	-$7.28-706.7%	$1.20-31.8%	$1.76+6.7%	$1.65+55.7%	$1.06-39.8%	$1.76+2.3%	$1.72-5.0%	$1.81
Diluted Shares (Avg)	N/A	77M+0.2%	77M-0.8%	77M+1.5%	76M+1.0%	75M+18.9%	64M+4.9%	61M	N/A	60M-1.8%	61M-1.6%	62M-0.2%	62M-0.7%	63M-0.3%	63M-0.1%	63M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$613.2M-10.1%	$627.8M-6.8%	$709.0M	$697.3M+1.5%	$681.9M+3.3%	$673.9M-74.2%	N/A	$686.8M-73.5%
Cost of Revenue	$349.8M-2.1%	$349.8M-1.4%	$385.7M	$375.1M+5.6%	$357.3M+3.8%	$354.6M-82.9%	N/A	$355.1M-82.7%
Gross Profit	$263.4M-18.9%	$278.0M-47.1%	$116.5M	$322.2M-42.4%	$324.6M-40.3%	$526.0M-1.8%	N/A	$559.7M+3.9%
SG&A Expenses	$243.6M-9.1%	$255.2M-2.7%	$271.5M	$265.8M-2.4%	$267.9M-0.8%	$262.4M-45.1%	N/A	$272.3M-39.8%
Operating Income	-$35.1Mn/m	$17.1M-13.5%	$20.9M	$26.5M-14.8%	-$39.7M-334.7%	$19.8M+104.1%	N/A	$31.1M+30.4%
EBITDA	$30.6M+832.5%	$78.9M+25.8%	$50.8M	$125.2M+35.1%	$3.3M-95.9%	$62.7M-25.2%	N/A	$92.7M-4.9%
Interest Expense	$34.5M+32.8%	$32.3M-4.7%	$18.2M	$29.0M+0.3%	$26.0M+1.6%	$34.0M-4.8%	N/A	$29.0M-24.1%
Income Tax	$1.4Mn/m	-$9.8Mn/m	$1.5M	$2.0Mn/m	-$1.1Mn/m	-$1.6Mn/m	N/A	-$303Kn/m
Net Income	-$89.1Mn/m	-$6.5Mn/m	-$56.3M	-$150.3Mn/m	-$869.1Mn/m	-$25.0Mn/m	N/A	-$12.8Mn/m
EPS (Basic)	-$1.16n/m	-$0.08n/m	-$0.76n/m	-$1.94n/m	-$11.30n/m	-$0.32n/m	-$3.86-1708.3%	-$0.17n/m
EPS (Diluted)	-$1.16n/m	-$0.08n/m	-$0.76n/m	-$1.94n/m	-$11.30n/m	-$0.32n/m	-$3.86-1708.3%	-$0.16n/m
Diluted Shares (Avg)	77M-0.3%	76M-1.1%	N/A	77M-1.5%	77M+0.3%	77M+1.2%	N/A	78M+3.0%

Not reported in any period shown, so not listed: R&D Expenses.

ACH Balance Sheet

ACH quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$2.5B-47.3%	$4.7B-8.6%	$5.1B-5.4%	$5.4B+52.3%	$3.5B+6.0%	$3.3B-8.4%	$3.6B-3.5%	$3.8B+11.8%	$3.4B+24.2%	$2.7B-2.0%	$2.8B+1.4%	$2.7B+17.7%	$2.3B+5.0%	$2.2B+13.7%	$1.9B
Current Assets	$547.9M-72.9%	$2.0B-3.9%	$2.1B-8.4%	$2.3B-1.1%	$2.3B+8.7%	$2.1B-11.3%	$2.4B-5.2%	$2.5B+16.3%	$2.2B+11.2%	$2.0B-0.6%	$2.0B+5.6%	$1.9B+8.3%	$1.7B+5.9%	$1.6B+6.8%	$1.5B
Cash & Equivalents	$282.0M+922.7%	$27.6M-88.7%	$243.0M+249.9%	$69.5M+24.7%	$55.7M-32.9%	$83.1M+23.9%	$67.0M+1.1%	$66.3M-36.6%	$104.5M-43.7%	$185.5M+15.2%	$161.0M+183.6%	$56.8M-44.3%	$101.9M+4.1%	$97.9M-28.0%	$135.9M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Inventory	$74.4M+10.1%	$67.6M-93.9%	$1.1B-16.7%	$1.3B-10.9%	$1.5B+21.3%	$1.2B+7.6%	$1.1B-10.0%	$1.3B+28.6%	$990.2M+8.1%	$916.3M-2.6%	$940.8M+7.8%	$872.5M+13.1%	$771.7M+1.0%	$763.8M-5.3%	$806.4M
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$1.2B0.0%	$1.2B-25.1%	$1.6B+0.1%	$1.6B+319.5%	$390.2M-1.0%	$394.1M+0.2%	$393.2M-5.1%	$414.1M-39.7%	$687.0M+65.6%	$414.9M-1.1%	$419.6M-0.9%	$423.3M+53.7%	$275.4M+0.2%	$274.9M+10.6%	$248.5M
Total Liabilities	$2.9B-28.4%	$4.1B-2.4%	$4.2B-6.1%	$4.4B+70.9%	$2.6B-1.0%	$2.6B-17.5%	$3.2B-2.3%	$3.3B+37.9%	$2.4B+34.3%	$1.8B-1.3%	$1.8B+2.1%	$1.7B+34.3%	$1.3B+4.7%	$1.2B+20.7%	$1.0B
Current Liabilities	$947.1M-48.9%	$1.9B-2.1%	$1.9B+20.8%	$1.6B+16.6%	$1.3B-0.1%	$1.3B-5.0%	$1.4B-3.8%	$1.5B+12.4%	$1.3B+26.6%	$1.0B-2.7%	$1.1B+10.0%	$966.6M-2.4%	$990.2M+7.0%	$925.6M+26.4%	$732.4M
Non-Current Liabilities	$2.0B-11.4%	$2.2B-2.6%	$2.3B-20.8%	$2.9B+129.2%	$1.3B-1.9%	$1.3B-27.6%	$1.8B-1.0%	$1.8B+69.7%	$1.1B+45.4%	$723.1M+0.8%	$717.6M-7.8%	$778.0M+151.9%	$308.8M-2.0%	$315.1M+6.7%	$295.2M
Long-Term Debt	$1.8B+0.1%	$1.8B-4.9%	$1.9B-23.9%	$2.5B+162.0%	$947.5M-3.9%	$986.0M-34.6%	$1.5B-8.5%	$1.6B+83.0%	$900.7M+59.5%	$564.6M-0.7%	$568.5M-6.6%	$608.6M+186.0%	$212.8M-1.2%	$215.4M+1.3%	$212.7M
Total Equity	-$461.0M-178.6%	$586.4M-38.0%	$945.3M-2.2%	$966.7M+3.0%	$938.5M+31.8%	$712.1M+54.1%	$462.2M-10.9%	$518.4M-48.9%	$1.0B+5.8%	$960.0M-3.3%	$992.6M+0.2%	$990.8M-3.2%	$1.0B+5.3%	$972.5M+5.9%	$918.1M
Retained Earnings	-$1.1B-4075.7%	$27.2M-92.6%	$368.7M-10.1%	$410.0M+5.8%	$387.6M+132.1%	$167.0M+21.2%	$137.8M-31.3%	$200.7M-70.9%	$690.7M+0.8%	$685.5M-3.0%	$706.9M+3.1%	$685.8M-0.8%	$691.5M+4.9%	$659.0M+6.4%	$619.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.1B-49.3%	$2.4B-50.3%	$2.5B-47.3%	$4.0B-20.6%	$4.2B-21.7%	$4.9B-6.8%	$4.7B-8.6%	$5.1B-0.8%
Current Assets	$271.4M-88.2%	$588.5M-73.3%	$547.9M-72.9%	$2.1B+0.7%	$2.3B-1.2%	$2.2B-1.3%	$2.0B-3.9%	$2.1B-0.6%
Cash & Equivalents	$7.7M-80.0%	$336.9M+466.8%	$282.0M+922.7%	$32.8M-27.8%	$38.3M-84.3%	$59.4M-75.7%	$27.6M-88.7%	$45.5M-78.9%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Inventory	$73.3M+5.9%	$65.3M-95.4%	$74.4M+10.1%	$63.8M-94.9%	$69.2M-94.4%	$1.4B+23.1%	$67.6M-93.9%	$1.2B+14.6%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Goodwill	$1.2B0.0%	$1.2B-7.8%	$1.2B0.0%	$1.2B-25.2%	$1.2B-24.9%	$1.3B-18.6%	$1.2B-25.1%	$1.6B+0.4%
Total Liabilities	$2.7B-40.1%	$2.9B-32.8%	$2.9B-28.4%	$4.5B+6.2%	$4.4B-0.2%	$4.3B-0.6%	$4.1B-2.4%	$4.2B-0.7%
Current Liabilities	$666.2M-75.1%	$1.2B-38.6%	$947.1M-48.9%	$2.5B+27.5%	$2.7B+25.5%	$2.0B+1.4%	$1.9B-2.1%	$1.9B+11.7%
Non-Current Liabilities	$2.0B+13.1%	$1.7B-27.9%	$2.0B-11.4%	$2.0B-12.0%	$1.8B-23.8%	$2.3B-2.3%	$2.2B-2.6%	$2.3B-9.3%
Long-Term Debt	$1.7B+7.7%	$1.5B-19.8%	$1.8B+0.1%	$1.8B-0.4%	$1.6B-14.8%	$1.9B-2.5%	$1.8B-4.9%	$1.8B-12.8%
Total Equity	-$550.9Mn/m	-$464.8M-181.4%	-$461.0M-178.6%	-$429.5M-148.0%	-$281.0M-131.9%	$571.0M-37.7%	$586.4M-38.0%	$895.7M+1.0%
Retained Earnings	-$1.2Bn/m	-$1.1B-106592.2%	-$1.1B-4075.7%	-$1.0B-438.3%	-$871.9M-376.9%	$1.0M-99.7%	$27.2M-92.6%	$302.1M-13.9%

Not reported in any period shown, so not listed: Accounts Receivable.

ACH Cash Flow Statement

ACH quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$180.4M	-$101.8M-163.0%	$161.5M-78.2%	$740.7M+127.9%	$325.0M+161.7%	$124.2M-63.4%	$339.2M+104.2%	$166.1M+43.7%	$115.6M+103.6%	$56.8M-69.8%	$187.7M-30.5%	$270.2Mn/m	-$3.8M-102.7%	$140.6M-35.7%	$218.5M+219.4%	$68.4M
Depreciation & Amortization	N/A	$214.5M+18.3%	$181.3M-13.8%	$210.4M-8.0%	$228.7M+152.3%	$90.6M-2.9%	$93.3M-20.0%	$116.7M+14.5%	$101.9M+71.5%	$59.4M+7.3%	$55.4M-16.0%	$66.0M+4.1%	$63.4M+25.3%	$50.6M+27.7%	$39.6M+16.0%	$34.1M
Stock-Based Compensation	N/A	$12.9M-22.6%	$16.6M+15.6%	$14.4M-31.4%	$21.0M-16.1%	$25.0M+25.0%	$20.0M+26.6%	$15.8M-3.5%	$16.4M+37.5%	$11.9M-1.1%	$12.0M+6.5%	$11.3M+37.8%	$8.2M+28.6%	$6.4M+12.0%	$5.7M+0.4%	$5.7M
Capital Expenditures	$176.8M	$191.0M+12.1%	$170.3M-1.2%	$172.4M+9.0%	$158.1M+285.7%	$41.0M-18.7%	$50.4M+18.9%	$42.4M-5.5%	$44.9M+29.6%	$34.6M+70.5%	$20.3M-1.1%	$20.5M-57.6%	$48.4M+72.2%	$28.1M+186.0%	$9.8M-60.6%	$25.0M
Free Cash Flow	-$357.2M	-$292.7Mn/m	-$8.8M-101.5%	$568.3M+240.5%	$166.9M+100.6%	$83.2M-71.2%	$288.8M+133.5%	$123.7M+74.9%	$70.7M+219.1%	$22.2M-86.8%	$167.4M-33.0%	$249.7Mn/m	-$52.2M-146.4%	$112.4M-46.1%	$208.7M+380.4%	$43.4M
Investing Cash Flow	$268.2M	$144.4Mn/m	-$116.5Mn/m	-$137.3Mn/m	-$1.8Bn/m	-$53.6M-167.0%	$80.1Mn/m	-$51.9Mn/m	-$815.8Mn/m	-$416.6Mn/m	-$24.7Mn/m	-$36.5Mn/m	-$317.3Mn/m	-$57.1M	N/A	N/A
Financing Cash Flow	-$157.3M	$188.1Mn/m	-$267.6Mn/m	-$417.3M-127.9%	$1.5Bn/m	-$129.5Mn/m	-$379.4Mn/m	-$130.2M-118.6%	$701.1M+157.0%	$272.8Mn/m	-$142.7Mn/m	-$124.9M-144.8%	$278.6Mn/m	-$82.0M	N/A	N/A
Dividends Paid	N/A	N/A	N/A	$0n/m	$0-100.0%	$731K+12.8%	$648K-87.6%	$5.2M-89.2%	$48.2M-23.7%	$63.2M-0.4%	$63.4M-0.4%	$63.7M+0.9%	$63.1M+3.9%	$60.7M+9.1%	$55.7M+9.4%	$50.9M
Share Buybacks	N/A	$10.2M	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$5.0M-93.0%	$71.0M+255.1%	$20.0M+101.3%	$9.9M-47.4%	$18.9M+25.8%	$15.0M-7.0%	$16.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$26.0M-169.1%	-$50.1Mn/m	$68.2M-4.0%	-$172.5M-731.8%	$37.6M-67.6%	-$35.1Mn/m	$71.0M-36.5%	$27.3M-82.7%
Depreciation & Amortization	$65.7M+52.8%	$61.7M+43.9%	$29.9M	$98.8M+60.3%	$43.0M-32.7%	$42.9M-42.1%	N/A	$61.6M-16.3%
Stock-Based Compensation	N/A	$3.1M-30.1%	N/A	N/A	N/A	$4.4M-35.6%	N/A	$5.7M-1.1%
Capital Expenditures	$47.6M-17.4%	$41.6M-9.1%	$13.1M-41.0%	$74.4M+29.1%	$57.6M+29.8%	$45.8M-0.4%	$22.3M-55.8%	$57.7M+20.8%
Free Cash Flow	-$73.6Mn/m	-$91.7Mn/m	$55.1M+12.9%	-$246.9Mn/m	-$20.0M-127.9%	-$80.9Mn/m	$48.7M-20.6%	-$30.3M-127.7%
Investing Cash Flow	-$31.2Mn/m	$53.9Mn/m	$285.0Mn/m	-$39.5Mn/m	-$52.9Mn/m	-$48.2Mn/m	-$52.3Mn/m	-$27.2Mn/m
Financing Cash Flow	-$272.0M-958.0%	$51.1M-44.9%	-$117.5Mn/m	$181.1Mn/m	$31.7Mn/m	$92.8M+74.0%	-$43.1Mn/m	-$199.6Mn/m
Share Buybacks	N/A	$0-100.0%	$3.5M	$0n/m	$5.2Mn/m	$1.5Mn/m	N/A	$0

Not reported in any period shown, so not listed: Dividends Paid.

ACH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACH quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	46.7%-36.1pp	82.8%-0.5pp	83.3%+64.9pp	18.4%+2.9pp	15.5%+0.4pp	15.1%+2.8pp	12.3%+0.9pp	11.4%-1.2pp	12.6%+0.4pp	12.2%-0.2pp	12.4%0.0pp	12.4%+0.1pp	12.3%+1.9pp	10.4%+0.5pp	9.9%
Operating Margin	1.0%+9.1pp	-8.1%-13.3pp	5.2%+3.8pp	1.4%-2.3pp	3.8%+1.4pp	2.4%+1.6pp	0.8%+4.5pp	-3.7%-4.7pp	1.0%-1.1pp	2.1%0.0pp	2.1%+0.4pp	1.7%-0.5pp	2.2%0.0pp	2.2%-0.1pp	2.4%
Net Margin	-39.9%-26.3pp	-13.5%-11.9pp	-1.6%-1.8pp	0.2%-2.0pp	2.3%+1.9pp	0.4%+1.0pp	-0.7%+4.0pp	-4.6%-5.4pp	0.8%-0.3pp	1.1%+0.1pp	1.1%+0.4pp	0.7%-0.5pp	1.2%0.0pp	1.2%-0.1pp	1.3%
Return on Equity	N/A	-61.9%-57.5pp	-4.4%-6.7pp	2.3%-21.3pp	23.6%+19.4pp	4.2%+17.7pp	-13.5%+70.8pp	-84.3%-91.5pp	7.2%-4.2pp	11.3%+0.9pp	10.4%+3.7pp	6.7%-4.1pp	10.8%-0.4pp	11.2%-1.3pp	12.6%
Return on Assets	-44.9%-37.1pp	-7.8%-7.0pp	-0.8%-1.2pp	0.4%-5.9pp	6.3%+5.4pp	0.9%+2.6pp	-1.7%+9.9pp	-11.6%-13.7pp	2.2%-1.8pp	4.0%+0.3pp	3.7%+1.3pp	2.4%-2.3pp	4.8%-0.2pp	4.9%-1.0pp	5.9%
Current Ratio	0.58-0.5x	1.090.0x	1.11-0.4x	1.47-0.3x	1.73+0.1x	1.59-0.1x	1.700.0x	1.72+0.1x	1.67-0.2x	1.900.0x	1.86-0.1x	1.93+0.2x	1.740.0x	1.76-0.3x	2.08
Debt-to-Equity	N/A	3.07+1.1x	2.00-0.6x	2.57+1.6x	1.01-0.4x	1.38-1.9x	3.26+0.1x	3.18+2.3x	0.89+0.3x	0.590.0x	0.570.0x	0.61+0.4x	0.210.0x	0.220.0x	0.23
Liabilities-to-Equity	N/A	6.94+2.5x	4.41-0.2x	4.59+1.8x	2.77-0.9x	3.68-3.2x	6.88+0.6x	6.28+4.0x	2.32+0.5x	1.830.0x	1.790.0x	1.76+0.5x	1.270.0x	1.28+0.2x	1.12
Asset Turnover	1.13+0.6x	0.58+0.1x	0.50-1.3x	1.85-0.9x	2.77+0.2x	2.540.0x	2.530.0x	2.50-0.3x	2.76-0.8x	3.58+0.1x	3.52+0.1x	3.45-0.5x	3.90-0.1x	4.00-0.4x	4.43
FCF Margin	-10.6%-10.3pp	-0.3%-22.6pp	22.3%+20.6pp	1.7%+0.8pp	0.9%-2.6pp	3.4%+2.1pp	1.3%+0.6pp	0.8%+0.5pp	0.2%-1.5pp	1.7%-0.8pp	2.6%+3.1pp	-0.5%-1.8pp	1.2%-1.1pp	2.4%+1.8pp	0.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	43.0%-4.6pp	44.3%-33.8pp	16.4%	46.2%-35.3pp	47.6%-34.8pp	78.1%+57.6pp	N/A	81.5%+60.7pp
Operating Margin	-5.7%+0.1pp	2.7%-0.2pp	2.9%	3.8%-0.7pp	-5.8%-8.4pp	2.9%+2.6pp	N/A	4.5%+3.6pp
Net Margin	-14.5%	-1.0%+2.7pp	-7.9%	-21.6%-19.7pp	-127.4%	-3.7%-2.9pp	N/A	-1.9%-1.6pp
Return on Equity	N/A	N/A	N/A	N/A	N/A	-4.4%-2.0pp	N/A	-1.4%-0.7pp
Return on Assets	-4.2%+16.7pp	-0.3%+0.2pp	-2.3%	-3.7%-3.5pp	-20.9%-20.3pp	-0.5%-0.1pp	N/A	-0.3%-0.1pp
Current Ratio	0.41-0.5x	0.49-0.6x	0.58-0.5x	0.86-0.2x	0.86-0.2x	1.130.0x	1.090.0x	1.09-0.1x
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	3.32+1.2x	3.07+1.1x	2.06-0.3x
Liabilities-to-Equity	N/A	N/A	N/A	N/A	N/A	7.51+2.8x	6.94+2.5x	4.70-0.1x
Asset Turnover	0.29+0.1x	0.26+0.1x	0.29	0.170.0x	0.160.0x	0.14-0.4x	N/A	0.14-0.4x
FCF Margin	-12.0%-9.1pp	-14.6%-2.6pp	7.8%	-35.4%-31.0pp	-2.9%-13.8pp	-12.0%-8.2pp	N/A	-4.4%-8.6pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Note: Shareholder equity is negative (-$461.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.58), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Where Accendra Health, Inc. Ranks

Frequently Asked Questions

What is Accendra Health, Inc.'s annual revenue?

Accendra Health, Inc. (ACH) reported $2.8B in total revenue for fiscal year 2025. This represents a 3.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Accendra Health, Inc.'s revenue growing?

Accendra Health, Inc. (ACH) revenue grew by 3.1% year-over-year, from $2.7B to $2.8B in fiscal year 2025.

Is Accendra Health, Inc. profitable?

No, Accendra Health, Inc. (ACH) reported a net loss of $302.1M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $1.1B, with a net profit margin of -39.9%.

What is Accendra Health, Inc.'s EBITDA?

Accendra Health, Inc. (ACH) had EBITDA of $242.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Accendra Health, Inc. have?

As of fiscal year 2025, Accendra Health, Inc. (ACH) had $282.0M in cash and equivalents against $1.8B in long-term debt.

What is Accendra Health, Inc.'s gross margin?

Accendra Health, Inc. (ACH) had a gross margin of 46.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Accendra Health, Inc.'s operating margin?

Accendra Health, Inc. (ACH) had an operating margin of 1.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Accendra Health, Inc.'s net profit margin?

Accendra Health, Inc. (ACH) had a net profit margin of -39.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Accendra Health, Inc.'s free cash flow?

Accendra Health, Inc. (ACH) recorded an outflow of $292.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Accendra Health, Inc.'s operating cash flow?

Accendra Health, Inc. (ACH) recorded an outflow of $101.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Accendra Health, Inc.'s total assets?

Accendra Health, Inc. (ACH) had $2.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Accendra Health, Inc.'s capital expenditures?

Accendra Health, Inc. (ACH) invested $191.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Accendra Health, Inc. buy back shares?

Yes, Accendra Health, Inc. (ACH) spent $10.2M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Accendra Health, Inc. have outstanding?

Accendra Health, Inc. (ACH) had 76M shares outstanding as of fiscal year 2025.

What is Accendra Health, Inc.'s current ratio?

Accendra Health, Inc. (ACH) had a current ratio of 0.58 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Accendra Health, Inc.'s return on assets (ROA)?

Accendra Health, Inc. (ACH) had a return on assets of -44.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Accendra Health, Inc.'s P/E ratio?

Accendra Health, Inc. (ACH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $19.5M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Accendra Health, Inc.'s price-to-sales ratio?

Accendra Health, Inc. (ACH) trades at 0.0x sales, its market capitalization divided by $2.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $19.5M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Accendra Health, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Accendra Health, Inc. (ACH) held $282.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $101.8M over that year. Dividing the one by the other, the reported balance equals about 33 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Accendra Health, Inc.'s debt-to-equity ratio negative or not reported?

Accendra Health, Inc. (ACH) has negative shareholder equity of -$461.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Accendra Health, Inc.'s Altman Z-Score?

Accendra Health, Inc. (ACH) has an Altman Z-Score of 0.36, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Accendra Health, Inc.'s Piotroski F-Score?

Accendra Health, Inc. (ACH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Accendra Health, Inc.'s earnings high quality?

Accendra Health, Inc. (ACH) reported a net loss of $1.1B while operations used $101.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Accendra Health, Inc. cover its interest payments?

Accendra Health, Inc. (ACH) has an interest coverage ratio of 0.26x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Accendra Health, Inc.?

Accendra Health, Inc. (ACH) scores 22 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.